The age floor matters more than the clearance itself. The FDA’s decision to clear C2N Diagnostics‘ PrecivityAD2 blood test for symptomatic adults as young as 40 sets a new boundary for clinical Alzheimer’s detection, one that directly intersects with the disease’s biology. Pathology accumulates for 15 to 20 years before symptoms surface, which means a 40-year-old presenting with early cognitive complaints could have amyloid burden dating to their mid-twenties. Validated in a clinical study of 1,142 subjects, PrecivityAD2 now puts a scalable, blood-based tool in front of that population for the first time at this age threshold.

The trial design implications are the part of this story the industry should internalize fastest. Eighty-three percent of active Alzheimer’s trials now incorporate a biomarker, and blood-based tests are replacing the PET scans and lumbar punctures that historically priced out large-scale, early-phase screening. PrecivityAD2 extends that infrastructure downward in age, expanding the pool of trial-eligible participants who can be confirmed amyloid-positive through a routine blood draw rather than an imaging suite. That changes enrollment math and site feasibility calculations in meaningful ways.

The clearance also reflects how quickly the regulatory landscape for Alzheimer’s diagnostics has reorganized. Fujirebio’s Lumipulse G pTau217/β-Amyloid 1-42 Plasma Ratio received 510(k) clearance in May 2025 for adults 55 and older. PrecivityAD2 now pushes that cleared age floor 15 years younger, and the ADDF counts three FDA-cleared blood tests in the space within roughly 15 months. Each clearance raises the floor for what sponsors can plausibly promise in trial design documents: biomarker-confirmed enrollment is no longer a high-cost aspiration but an operational expectation for pivotal programs targeting early disease.

The specific marker to watch now is whether the 40-to-54 age cohort, previously outside the cleared indication for any Alzheimer’s blood test, begins appearing in amended trial protocols as a pre-specified enrichment stratum. If sponsors start filing amendments to include that younger symptomatic population in ongoing prevention and early-intervention studies, it will signal that PrecivityAD2’s age clearance has moved from regulatory milestone to active trial infrastructure within months, not years.

Source link: https://www.prnewswire.com/news-releases/fda-clearance-of-c2n-diagnostics-precivityad2-blood-test-advances-precision-medicine-for-alzheimers-building-on-groundwork-laid-by-early-addf-investment-302856858.html

+ posts

Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.